1,5-Diaryl-3-oxo-1,4-pentadienes: A case for antineoplastics with multiple targets

Current Medicinal Chemistry

Volumn 16, Issue 16, 2009, Pages 2001-2020

  Das, U ^a   Sharma, R K ^b   Dimmock, J R ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

1,5 Diaryl 3 oxo 1,4 pentadienes; 3,4 dihydro 1H naphthalen 2 ones; 4 piperidones; Anticancer activity; Antineoplastics; Cycloalkanones; Cytotoxicity; Diaryldienones

Indexed keywords

1,5 DIARYL 3 OXO 1,4 PENTADIENE; 3,4 DIHYDRO 1H NAPHTALEN 2 ONE; 3,5 BIS(BENZYLIDENE) 4 PIPERIDONE; ACYCLIC 1,5 DIARYL 3 OXO 1,4 PENTADIENE; ANTINEOPLASTIC AGENT; BIS(BENZYLIDENE)CYCLOALKANONE; CYCLOPENTADIENE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; N ACYL 3,5 BIS(BENZYLIDENE) 4 PIPERIDONE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CELL; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG POTENCY; DRUG STRUCTURE; HUMAN; IC 50; MITOCHONDRIAL RESPIRATION; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; REVIEW; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ALKADIENES; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS;

EID: 68449101830     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788682218     Document Type: Review

References (101)

1. Dimmock, J.R.; Wong, M.L.C. Bioactivities and potential uses in drug design of acyclic α,β-unsaturated ketones. Can. J. Pharm. Sci., 1976, 11, 35-53.
2. Dimmock, J.R.; Raghavan, S.K.; Logan, B.M.; Bigam, G.E. Antileukemic evaluation of some Mannich bases derived from 2-arylidene-1,3-diketones. Eur. J. Med. Chem., 1983, 18, 248-254.
3. Mutus, B.; Wagner, J.D.; Talpas, C.J.; Dimmock, J.R.; Phillips, O.A.; Reid, R.S. 1-p-Chlorophenyl-4,4-dimethyl-5-diethylamino-1-penten-3-one hydrobromide, a sulfhydryl-specific compound which reacts irreversibly with protein thiols but reversibly with small molecular weight thiols. Anal. Biochem., 1989, 177, 237-243.
4. Benvenuto, J.A.; Connor, T.H.; Monteith, D.K.; Laidlaw, J.A.; Adams, S.C.; Matney, T.S.; Theiss, J.C. Degradation and inactivation of antitumor drugs. J. Pharm. Sci., 1993, 82, 988-991.
5. Okey, A.B.; Harper, P.A. In Principles of Medical Pharmacology; Kalant, H.; Grant, D.M.; Mitchell, J.; Eds.; 7th ed.; Elsevier: Toronto, Canada, 2007, p. 902.
6. Dimmock, J.R.; Elias, D.W.; Beazely, M.A.; Kandepu, N.M. Bioactivities of chalcones. Curr. Med. Chem., 1999, 6, 1125-1149.
7. Dimmock, J.R.; Kumar, P. Anticancer and cytotoxic properties of Mannich bases. Curr. Med. Chem., 1997, 4, 1-22.
8. Dimmock, J.R.; Sidhu, K.K.; Chen, M.; Reid, R.S.; Allen, T.M.; Kao, G.Y.; Truitt, G.A. Evaluation of some Mannich bases of cycloalkanones and related compounds for cytotoxic activity. Eur. J. Med. Chem., 1993, 28, 313-322.
9. Chen, G.; Waxman, D.J. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Biochem. Pharmacol., 1994, 47, 1079-1087.
10. Mitchell, J.B.; Russo, A. The role of glutathione in radiation and drug induced cytotoxicity. Br. J. Cancer, 1987, 55, 96-104.
11. Tsutsui, K.; Komuro, C.; Ono, K.; Nishidia, T.; Shibamoto, Y.; Takahashi, M.; Abe, M. Chemosensitization by buthionine sulfoximine in vivo. Int. J. Radiat. Oncol. Biol. Phys., 1986, 12, 1183-1186.
12. Workman, P.; Collins, I. In Cancer Drug Design and Discovery, Neidle, S., Ed.; Academic Press: London, 2008, p. 6.
13. Reidy, D.; Saltz, L. Targeted strategies in the treatment of metastatic colon cancer. J. Natl. Compr. Cancer Netw., 2007, 5, 983-990.
14. Espinoza-Fonseca, L.M. The benefits of the multi-target approach in drug design and discovery. Bioorg. Med. Chem., 2006, 14, 896-897.
15. Frantz, S. Playing dirty. Nature, 2005, 437, 942-943.
16. Galanski, M.; Keppler, B.K. Searching for the magic bullet: Anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anti-Cancer Agents Med. Chem., 2007, 7, 55-73.
17. Quinn, F.R.; Milne, G.W.A. Toxicities derived from anti-tumor screening data. Fundam. Appl. Toxicol., 1986, 6, 270-277
18. Jha, A.; Duffield, K.M. 3,5-Bis(arylmethylene)-4-piperidone derivatives as novel anticancer agents. Indian J. Chem., 2006, 45B, 2313-2320.
19. Dimmock, J.R.; Smith, L.M.; Smith, P.J. The reaction of some nuclear substituted acyclic conjugated styryl ketones and related Mannich bases with ethanethiol. Can. J. Chem., 1980, 58, 984-991.
20. Dimmock, J.R.; Taylor, W.G. Evaluation of nuclear-substituted styryl ketones and related compounds for antitumor and cytotoxic properties. J. Pharm. Sci., 1975, 64, 241-249.
21. Dimmock, J.R.; Patil, S.A.; Shyam, K. Evaluation of some Mannich bases of 1-aryl-ethanones and related ketones for anticonvulsant activities. Pharmazie, 1991, 46, 538-539.
22. Dimmock, J.R.; Arora, V.K.; Wonko, S.L.; Hamon, N.W.; Quail, J.W.; Jia, Z.; Warrington, R.C.; Fang, W.D.; Lee, J.S. 3,5-bis-Benzylidene-4-piperidones and related compounds with high activity towards P388 leukemia cells. Drug Des. Deliv., 1990, 6, 183-194.
23. Dimmock, J.R.; Arora, V.K.; Semple, H.A.; Lee, J.S.; Allen, T.M.; Kao, G.Y. 3,5-Bis-arylidene-1-methyl-4-piperidone methohalides and related compounds with activity against L1210 cells and DNA binding properties. Pharmazie, 1992, 47, 246-248.
24. Albert, A. Selective Toxicity, 7th ed., Chapman and Hall: London, 1985, pp. 642-643.
25. Dimmock, J.R.; Arora, V.K.; Duffy, M.J.; Reid, R.S.; Allen, T.M.; Kao, G.Y. Evaluation of some N-acyl analogues of 3,5-bis(arylidene)-4-piperidones for cytotoxic activity. Drug Des. Discov., 1992, 8, 291-299.
26. Dimmock, J.R.; Arora, V.K.; Quail, J.W.; Pugazhenthi, U.; Allen, T.M.; Kao, G.Y.; De Clercq, E. Cytotoxic evaluation of some 3,5-diarylidene-4-piperidones and various related quaternary ammonium compounds and analogs. J. Pharm. Sci., 1994, 83, 1124-1130.
27. Dimmock, J.R.; Padmanilayam, M.P.; Puthucode, R.N.; Nazarali, A.J.; Motaganahalli, N.L.; Zello, G.A.; Quail, J.W.; Oloo, E.O.; Kraatz, H.-B.; Prisciak, J.S.; Allen, T.M.; Santos, C.L.; Balzarini, J.; De Clercq, E.; Manavathu, E.K. A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues. J. Med. Chem., 2001, 44, 586-593.
28. Pandeya, S.N.; Dimmock, J.R. In An Introduction to Drug Design New Age International (P) Limited, Publishers: New Delhi, 1997, pp. 136, 137.
29. Dimmock, J.R.; Kandepu, N.M.; Hetherington, M.; Quail, J.W.; Pugazhenthi, U.; Sudom, A.M.; Chamankhah, M.; Rose, P.; Pass, E.; Allen, T.M.; Halleran, S.; Szydlowski, J.; Mutus, B.; Tannous, M.; Manavathu, E.K.; Myers, T.G.; De Clercq, E.; Balzarini, J. Cytotoxic activities of Mannich bases of chalcones and related compounds. J. Med. Chem., 1998, 41, 1014-1026,
30. Das, U.; Alcorn, J.; Shrivastav, A.; Sharma, R.K.; De Clercq, E.; Balzarini, J.; Dimmock, J.R. Design, synthesis and cytotoxic properties of novel 1-[4-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds. Eur. J. Med. Chem., 2007, 42, 71-80.
31. Das, U.; Das, S.; Bandy, B.; Stables, J.P.; Dimmock, J.R. N-Aroyl-3,5-bis(benzylidene)-4-piperidones: A novel class of antimycobacterial agents. Bioorg. Med. Chem., 2008, 16, 3602-3607.
32. Kawase, M.; Sakagami, H.; Motohashi, N.; Hauer, H.; Chatterjee, S.S.; Spengler, G.; Vigyikanne, A.V.; Molnár, A.; Molnár, J. Coumarin derivatives with tumor-specific cytotoxicity and multidrug resistance reversal study. In Vivo, 2005, 19, 705-712.
33. Das, U.; Molnár, J.; Baráth, Z.; Bata, Z.; Dimmock, J.R. 1-[4-(2-Aminoethoxy)phenylcarbonyl]- 3,5-bis-(benzylidene)-4- oxopiperidines: A novel series of highly potent revertants of P-glycoprotein associated multidrug resistance. Bioorg. Med. Chem. Lett., 2008, 18, 3484-3487.
34. Dimmock, J.R.; Jha, A.J.; Zello, G.A.; Quail, J.W.; Oloo, E.O.; Nienaber, K.H.; Kowalczyk, E.S.; Allen, T.M.; Santos, C.L.; De Clercq, E.; Balzarini, J.; Manavathu, E.K.; Stables, J.P. Cytotoxic N-[4-(3-aryl-3-oxo-1- propenyl)phenylcarbonyl]-3,5-bis (phenylmethylene)-4-piperidones and related compounds. Eur. J. Med. Chem., 2002, 37, 961-972.
35. Ducki, S. The development of chalcones as promising anticancer agents. IDrugs, 2007, 10, 42-46.
36. Go, M.L.; Wu, X.; Liu, X.L. Chalcones: An update on cytotoxic and chemopreventive properties. Curr. Med. Chem., 2005, 12, 483-499.
37. Dimmock, J.R.; Jha, A.; Zello, G.A.; Sharma, R.K.; Shrivastav, A.; Selvakumar, P.; Allen, T.M.; Santos, C.L.; Balzarini, J.; De Clercq, E.; Manavathu, E.K.; Stables, J.P. 3,5-Bis(phenylmethylene)-1- (N-arylmaleomyl)-4-piperidones: A novel group of cytotoxic agents. J. Enzyme Inhib. Med. Chem., 2003, 18, 325-332
38. Jha, A.; Mukherjee, C.; Prasad, A.K.; Parmar, V.S.; De Clercq, E.; Balzarini, J.; Stables, J.P.; Manavathu, E.K.; Shrivastav, A.; Sharma, R.K.; Nienaber, K.H.; Zello, G.A.; Dimmock, J.R. E,E,E-1-(4-Arylamino-4-oxo-2- butenoyl)-3,5-bis(arylidene)-4-piperidones: a topographical study of some novel potent cytotoxins. Bioorg. Med. Chem., 2007, 15, 5854-5865.
39. Boutin, J.A. Myristoylation. Cell Signal., 1997, 9, 15-35.
40. Peseckis, S.M.; Resh, M.D. Fatty acyl transfer by human N-myristoyltransferase is dependent upon conserved cysteine and histidine residues. J. Biol. Chem., 1994, 269, 30888-30892.
41. Raju, R.V.S.; Moyana, T.N.; Sharma, R.K. N-myristoyltransferase overexpression in human colorectal adenocarcinomas. Exp. Cell Res., 1997, 235, 145-154.
42. Paull, K.D.; Shoemaker, R.H.; Hodes, L.; Monks, A.; Scudiero, D.A.; Rubinstein, L.; Plowman, J.; Boyd, M.R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst., 1989, 21, 1088-1092.
43. Ypsilantis, P.; Tentes, I.; Assimakopoulos, S.F.; Kortsaris, A.; Scopa, C.D.; Simopoulos, C. Mesna ameliorates intestinal mucosa damage after ifosfamide administration in the rabbit at a dose-related manner. J. Surg. Res., 2004, 121, 84-91.
44. Haselberger, M.B.; Schwinghammer, T.L. Efficacy of mesna for prevention of hemorragic cystitis after high-dose cyclophosphamide therapy. Ann. Pharmacother., 1995, 29, 918-921.
45. Allan, S.G.; Smyth, J.F.; Hay, F.G.; Leonard, R.C.; Wolf, C.R. Protective effect of sodium-2-mercaptoethanesulfonate on the gastrointestinal toxicity and lethality of cis-diammine dichloroplatinum. Cancer Res., 1986, 46, 3569-3573.
46. Pati, H.N.; Das, U.; Quail, J.W.; Kawase, M.; Sakagami, H.; Dimmock, J.R. Cytotoxic 3,5-bis(benzylidene)piperidin-4-ones and N-acyl analogs displaying selective toxicity for malignant cells. Eur. J. Med. Chem., 2008, 43, 1-7.
47. Pati, H.N.; Das, U.; Das, S.; Bandy, B.; De Clercq, E.; Balzarini, J.; Kawase, M.; Sakagami, H.; Quail, J.W.; Stables, J.P.; Dimmock, J.R. The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl- 8-azabicyclo[3.2.1]octan- 3-ones and 3,5-bis(benzylidene)-1- methyl-4-piperidones. Eur. J. Med. Chem., 2009, 44, 54-62.
48. Topliss, J.G. A manual method for applying the Hansch approach to drug design. J. Med. Chem., 1977, 20, 463-469.
49. Hamon, N.W.; Bassendowski, D.L.; Wright, D.E., Dimmock, J.R.; Noble, L.M. Effect of antineoplastic and cytotoxic Mannich bases derived from conjugated styryl ketones on mitochondrial respiration in rat liver cells. J. Pharm. Sci., 1978, 67, 1539-1542.
50. Dimmock, J.R.; Hamon, N.W.; Noble, L.M.; Wright, D.E. Nuclear-substituted styryl ketone analogs: Effects on neoplasms, microorganisms, and mitochondrial respiration of tumorous and normal cells. J. Pharm. Sci., 1979, 68, 1033-1039.
51. Sun, A.; Shoji, M.; Lu, Y.J.; Liotta, D.C.; Snyder, J.P. Synthes of EF-24-tripeptide chloromethyl ketone: A novel curcumin-related anticancer drug delivery system. J. Med. Chem., 2006, 49, 3153-3158.
52. Shoji, M.; Snyder, J.P.; Liotta, D.D.; Sun, A. Cytotoxic compoundprotein conjugates as suppressors of tumor growth and angiogenesis. U.S. 2005/ 0069551 A1, March 31, 2005.
53. Adams, B.K.; Ferstl, E.M.; Davis, M.C.; Herold, M.; Kurtkaya, S.; Camalier, R.F.; Hollingshead, M.G.; Kaur, G.; Sausville, E.A.; Rickles, F.R.; Snyder, J.P.; Liotta, D.C.; Shoji, M. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg. Med. Chem., 2004. 12, 3871-3883.
54. Nam, N.H. Combretastatin A-4 analogues as antimitotic anti-tumor agents. Curr. Med. Chem., 2003, 10, 1697-1722.
55. Tozer, G.M.; Prise, V.E.; Wilson, J.; Locke, R.J.; Vojnovic, B.; Stratford, M.R.; Dennis, M.F.; Chaplin, D.J. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res., 1999, 59, 1626-1634.
56. Gomes, A.; Fernandes, E.; Silva, A.M.S.; Santos, C.M.M.; Pinto, D.C.G.A.; Cavaleiro, J.A.S.; Lima, J.L.F.C. 2-Styrylchromones: Novel strong scavengers of reactive oxygen and nitrogen species. Bioorg. Med. Chem., 2007, 15, 6027-6036.
57. Gomes, A.; Fernandes, E.; Garcia, M.B.Q.; Silva, A.M.S.; Pinto, D.C.G.A.; Santos, C.M.M.; Caveleiro, J.A.S.; Lima, J.L.F.C. Cyclic voltammetric analysis of 2-styrylchromanones: Relationship with the antioxidant activity. Bioorg. Med. Chem., 2008, 16, 7939-7943.
58. Youssef, K.M.; El-Sherbeny, M.A.; El-Shafie, F.S.; Faraq, H.A.; Al-Deeb, O.A.; Anadalla, S.A.S. Synthesis of curcumin analogues as potential antioxidant, cancer chemopreventive agents. Arch. Pharm. Pharm. Med. Chem., 2004, 337, 42-54.
59. Dimmock, J.R.; Sidhu, K.K.; Chen, M.; Li, J.; Quail, J.W.; Allen, T.M.; Kao, G.Y. Synthesis and cytotoxic evaluation of some cyclic arylidene ketones and related oximes, oxime esters and analogs. J. Pharm. Sci., 1994, 83, 852-858.
60. Dimmock, J.R.; Kumar, P.; Nazarali, A.J.; Motaganahalli, N.L.; Kowalchuk, T.P.; Beazely, M.A.; Quail, J.W.; Oloo, E.O.; Allen, T.M.; Szydlowski, J.; De Clercq, E.; Balzarini, J. Cytotoxic 2,6-bis(arylidene)cyclohexanones and related compounds. Eur. J. Med. Chem., 2000, 35, 967-977.
61. Wike-Hooley, J.L.; Haveman, J.; Reinhold, H.S. The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol., 1984, 2, 343-366.
62. Das, U.; Doroudi, A.; Das, S.; Bandy, B.; Balzarini, J.; De Clercq, E.; Dimmock, J.R.; E,E-2-Benzylidene-6-(nitrobenzylidene) cyclohexanones: Syntheses, cytotoxicity and an examination of their electronic, steric and hydrophobic properties. Bioorg. Med. Chem., 2008, 16, 6261-6268.
63. Bryla, J. In Inhibition of Mitochondrial Function; Erecińska, M.; Wilson, D.F., Eds.; Pergamon Press: Oxford, 1981, pp. 244-246.
64. Dimmock, J.R.; Das, U.; Gul, H.I.; Kawase, M.; Sakagami, H.; Baráth, Z.; Ocsovsky, I.; Molnár, J. 3-Arylidene-1-(4-nitrophenylmethylene)- 3,4-dihydro-1H- naphthalen-2-ones and related compounds displaying selective toxicity and reversal of multidrug resistance in neoplastic cells. Bioorg. Med. Chem. Lett., 2005, 15, 1633-1636.
65. Davis, R.; Das, U.; Mackay, H.; Brown, T.; Mooberry, S.L.; Dimmock, J.R.; Lee, M.; Pati, H. Syntheses and cytotoxic properties of the curcumin analogs 2,6-bis(benzylidene)-4-phenylcyclohexanones. Arch. Pharm. Chem. Life Sci., 2008, 341, 440-445.
66. Markaverich, B.M.; Gregory, R.R.; Alejandro, M.-A.; Clark, J.H.; Johnson, G.A.; Middleditch, B.S. Methyl p-hydroxyphenyllactate. J. Biol. Chem., 1988, 263, 7203-7210.
67. Markaverich, B.M.; Varma, R.S. Combination therapy using bioflavonoid compounds with anti-cancer drugs. PCTWO 93/01824, February 4, 1993.
68. Markaverich, B.M.; Schauweker, T.H.; Gregory, R.R.; Varma, M.; Kittrell, F.S.; Medina, D.; Varma, R.S. Nuclear type II sites and malignant cell proliferation: Inhibition by 2,6-bis-benzylidenecyclohexanones. Cancer Res., 1992, 52, 2482-2488.
69. Robinson, T.P.; Ehlers, T.; Hubbard, R.B. IV; Bai, X.; Arbiser, J.L.; Goldsmith, D.J.; Bowen, J.P. Design, synthesis, and biological evaluation of angiogenesis inhibitors: Aromatic enone and dienone analogues of curcumin. Bioorg. Med. Chem. Lett., 2003, 13, 115-117.
70. Dimmock, J. R.; Pamanilayam, M.P.; Zello, G.A.; Quail, J.W.; Oloo, E.O..; Prisciak, J.S.; Kraatz, H.-B.; Cherkasov, A.; Lee, J.S.; Allen, T.M.; Santos, C.L.; Manavathu, E.K.; De Clercq, E.; Balzarini, J.; Stables, J.P. Cytotoxic 1,3-diarylidene-2-tetralones and related compounds. Eur. J. Med. Chem., 2002, 37, 813-824
71. Das, U.; Gul, H.I.; Alcorn, J.; Shrivastav, A.; George, T.; Sharma, R.K.; Nienaber, K.H.; De Clercq, E.; Balzarini, J.; Kawase, M.; Kan, N.; Tanaka, T.; Tari, S.; Werbovetz, K.A.; Yakovich, A.; Manavathu, E.K.; Stables, J.P.; Dimmock, J.R. Cytotoxic 5-aryl-1-(4-nitrophenyl)-3-oxo-1,4-pentadienes mounted on alicyclic scaffolds. Eur. J. Med. Chem., 2006, 41, 577-585
72. Petit, G.R.; Singh, S.B.; Boyd, M.R.; Hamel, E.; Petit, R.K.; Schmidt, J.M.; Hogan, F. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6. J. Med. Chem., 1995, 38, 1666-1672.
73. Jha, A.; Zhao, J.; Cameron, T.S.; De Clercq, E.; Balzarini, J.; Manavathu, E.K.; Stables, J.P. Design, synthesis and biological evaluation of novel curcumin analogues as anti-neoplastic agents. Lett. Drug Des. Discov., 2006, 3, 304-310.
74. Lin, L.; Nyarko, A.K.; Baston, K.F.; Wu, C.-C.; Su, C.-Y.; Shih, C.C.-Y.; Lee, K.-H. Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J. Med. Chem., 2006, 49, 3963-3972.
75. Sardjiman, S.S.; Reksohadiprodjo, M.S.; Hakim, L.; van der Goot, H.; Timmerman, H. 1,5-Diphenyl-1,4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. Eur. J. Med. Chem., 1997, 32, 625-630.
76. Weber, W.M.; Hunsaker, L.A.; Abcouwer, S.F.; Deck, L.M.; Vander Jagt, D.L. Anti-oxidant activities of curcumin and related enones. Bioorg. Med. Chem., 2005, 13, 3811-3820.
77. Anto, R.J.; Sukumaran, K.; Kuttan, G.; Rao, M.N.A.; Subbaraju, V.; Kuttan, R. Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Lett., 1995, 97, 33-37.
78. Cramer, R.D., III; Patterson, D.E.; Bunce, J.D. Comparative Molecular Field Analysis (COMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 1988, 110, 5959-5967.
79. Cramer, R.D., III; Bunce, J.D.; Patterson, D.E. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat., 1988, 7, 18-25.
80. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (COMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem., 1994, 37, 4130-4146.
81. Patel, M.R.; Dimmock, J.R.; Talele, T.T. CoMFA and CoMSIA studies on 1,3-bis(benzylidene)-3,4-dihydro-1H-naphthalen-2-one, 2,6-bis(benzylidene)cyclohexanone, and 3,5-bis(benzylidene)-4-piperidone series of cytotoxic compounds. J. Chem. Inf. Model., 2007, 47, 2110-2123.
82. Radin, N.S. Drug design: Hiding in full view. Drug Dev. Res., 2008, 69, 15-25.
83. Martirosyan, A.O.; Gasparyan, S.P.; Oganesyan, V.E.; Mantirosyan, V.V.; Chachoyan, A.A.; Kazaryan, É.V.; Garibdzhanyan, B.T. Synthesis, antibacterial and antitumor activity of semisynthetic penicillins and cephalosporins based on new sarcomycin analogs. Pharm. Chem. J., 2005, 39, 67-69.
84. Ohori, H.; Yamakoshi, H.; Tomizawa, M.; Shibuya, M.; Kakudo, Y.; Takahashi, A.; Takahashi, S.; Kato, S.; Suzuki, T.; Ishioka, C.; Iwabuchi, Y.; Shibata, H. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol. Cancer Ther., 2006, 5, 2563-2571.
85. Aleo, E.; Henderson, C.J.; Fontanini, A.; Solazzo, B.; Brancolini, C. Identification of new compounds that trigger apoptosome independent caspase activation and apoptosis. Cancer Res., 2006, 66, 9235-9244.
86. Henderson, C.J.; Aleo, E.; Fontanini, A.; Maestro, R.; Paroni, G.; Brancolini, C. Caspase activation and apoptosis in response to proteasome inhibitors. Cell Death Differ., 2005, 12, 1240-1254.
87. Mullally, J.E.; Fitzpatrick, F.A. Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Mol. Pharmacol., 2002, 62, 351-358.
88. Chang, J.-Y.; Hsieh, H.-P.; Pan, W.-Y.; Liou, J.-P.; Bey, S.-J.; Chen, L.-T.; Song, J.-S. Dual inhibition of topoisomerase I and tubulin polymerization by BPROY007, a novel cytotoxic agent. Biochem. Pharmacol., 2003, 65, 2009-2019.
89. Juang, S.-H.; Pan, W.-Y.; Kuo, C.-C.; Liou, J.-P.; Hung, Y.-M.; Chen, L.-T.; Hsieh, H.-P.; Chang, J.-Y. A novel bisbenzylidenecyclopentanone derivative, BPROY007, inducing a rapid caspase activation involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid carcinoma cells. Biochem. Pharmacol., 2004, 68, 293-303.
90. Yoo, M.-H.; Xu, X.-M.; Carlson, B.A.; Gladyshev, V.N.; Hatfield, D.L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem., 2006, 281, 13005-13008.
91. Fang, J.; Lu, J.; Holmgren, A. Thioredoxin reductase is irreversibly modified by curcumin: A novel molecular mechanism for its anticancer activity. J. Biol. Chem., 2005, 280, 25284-25290
92. Qiu, X.; Liu, Z.; Shao, W.-Y.; Liu, X.; Jing, D.-P.; Yu, Y.-J.; An, L.-K.; Huang, S.-L.; Bu, X.-Z.; Huang, Z.-S.; Gu, L.-Q. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors. Bioorg. Med. Chem., 2008, 16, 8035-8041.
93. Jardines, L.; Weiss, M.; Fowble, B.; Green, M. Neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology, 1993, 61, 268-282.
94. Das, U.; Selvakumar, P.; Sharma, R.K.; Haas, T.H.; Dimmock, J.R. N-Acyl-3,5-bis(arylidene)-4-piperidones and related compounds which stimulate fyn kinase. J. Enzyme Inhib. Med. Chem., 2007, 22, 451-455.
95. Markaverich, B.M.; Clark, J.H. Two binding sites for estradiol in rat uterine nuclei: Relationship to uterotropic response. Endocrinology, 1979, 105, 1458-1462.
96. Markaverich, B.M.; Upchurch, S.; Clark, J.H. Progesterone and dexamethasone antagonism of uterine growth: A role for a second nuclear binding site for estradiol in estrogen action. J. Steroid Biochem., 1981, 14, 125-132.
97. Achanta, G.; Modzelewska, A.; Feng, L.; Khan, S.R.; Huang, P. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol. Pharmacol., 2006, 70, 426-433.
98. Andela, V.B.; Gordon, A.H.; Zotalis, G.; Rosier, R.N.; Goater, J.J.; Lewis, G.D.; Schwartz, E.M.; Puzas, J.E.; O'Keefe, R.J. NFkappa B: A pivotal transcription factor in prostate cancer metastasis to bone. Clin. Orthop. Relat. Res., 2003, 415(Suppl), S75-S85.
99. Weber, W.M.; Hunsaker, L.A.; Roybal, C.N.; Bobrovnikova-Marjon, E.V.; Abcouwer, S.F.; Royer, R.E.; Deck, L.M.; Vander Jagt, D.L. Activation of NFκB is inhibited by curcumin and related enones. Bioorg. Med. Chem., 2006, 14, 2450-2461.
100. Ligeret, H.; Barthélémy, S.; Doulakas, G.B.; Carrupt, P.-A.; Tillement, J.-P.; Labidalle, S.; Morin, D. Fluoride curcumin derivatives: New mitochondrial uncoupling agents. FEBS Lett., 2004, 569, 37-42.
101. Das, S.; Das, U.; Bandy, B.; Gorecki, D.K.J.; Dimmock, J.R. The effect of some 1-[4-(2-diethylaminoethoxy) phenylcarbonyl]-3,5-bis(benzylidene)- 4-piperidone methoiodides and related compounds on respiration and swelling of rat liver mitochondria. Pharmazie, 2008, 63, 827-829.